<DOC>
	<DOC>NCT00825955</DOC>
	<brief_summary>The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib</brief_summary>
	<brief_title>Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Histologic or cytologic confirmed diagnosis of HCC Advanced disease defined as (i) disease not eligible for surgical or locoregional therapy or (ii) disease progressive after surgical or locoregional therapy Patient has failed â‰¥ 14 days of Sorafenib treatment Cirrhotic status of ChildPugh Class A or B with a score of 7 Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 Subjects who have a life expectancy of at least 8 weeks Adequate hematologic, hepatic, and renal function women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy Previous or concurrent cancer that is distinct in primary site History of active cardiac disease Thrombotic or embolic events within the past 6 months Any other hemorrhage/bleeding event &gt; Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within 4 weeks Inability to swallow tablets or untreated malabsorption syndrome History of human immunodeficiency virus (HIV) infection Prior use of systemic investigational agents for HCC (except for Sorafenib)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>